Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring
Table 1
Summary of studies that evaluated the association between ribavirin concentration (CRBV) or AUC and sustained virological response (SVR) rate among HCV monoinfected patients (modified from Solas et al. [89])
Jen et al. [21] 929 naive patients whatever HCV-genotype
CRBV at W4 is a predictive value of SVR. CRBV at W4 >3.5–4 µg/mL is associated with 49% of SVR.
Larrat et al. [69] 24 naive HCV genotype 1 patients
CRBV at W12 and at W24 is significantly higher among patients who achieve SVR compared to null-responders. CRBV at W12 and at W24 >3 µg/mL is associated with SVR.
Tsubota et al. [90] 27 naive HCV genotype 1 patients
CRBV at W4 >2 µg/mL is predictive of SVR.
Maynard et al. [8] 31 HCV genotype 1 patients (8 naive and 23 nonresponder to a previous treatment)
CRBV at W4 >2 µg/mL is predictive of SVR.
Arase et al. [91] 68 naive HCV genotype 1 patients
CRBV at W8 >3 µg/mL is predictive of SVR
Lindahl et al. [78] 10 naive HCV genotype 1 patients
High ribavirin doses were used to achieve a CRBV at W4 >3.6 µg/mL and a CRBV at W12 >3.5 µg/mL in all patients. 9/10 achieved SVR.
Loustaud-Ratti et al. [70] 28 naive HCV genotype 1 patients
AUC at D0 correlated with AUC at D0. Both are predictive of SVR. AUC at D0 > 1755 µg·h/L is predicitve of SVR (Se = 72% and Spe = 85%).
